Rapid adoption of award winning study startup solutions drive market penetration in Life Sciences industry
SAN FRANCISCO, July 1, 2015 -- goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today unprecedented growth in serving pharmaceutical, biotech and CRO companies.
"There is intense pressure to speed clinical trials and restrain costs, but inefficiencies tied to complicated protocols, globalization, and paper-based methods have stalled these efforts," said Sujay Jadhav, goBalto's CEO. "The current status of clinical trials has encouraged Industry leaders, to embrace cloud-based solutions. Our study startup methodology aligns with the goal of faster development by significantly impacting cycle times, leading to greater cost savings and faster market entry, making valuable therapies available to patients sooner."
With recent multiple enterprise expansion's goBalto now services three of the top 5 CROs and more than two-thirds of the top 20 pharma's, managing their clinical trial documents globally, representing > 70% of clinical trial sites in phase II & III of the top 25 pharma companies.
With over 2,000 pharmaceutical and CRO users in more than 60 countries using Activate to manage, track, and complete study startup tasks, goBalto has the largest industry-proven set of country specific regulatory business process workflows.
Ross Pettit, SVP, Clinical Development Operations at Infinity Pharmaceuticals stated, "Many of the steps involved in study startup create delays, but with the deployment of goBalto Activate, a proven, purpose-build cloud-based study startup solution we can make a disruptive impact. Our partnership is critical to our goal of achieving automation in our clinical trials processes and our mission of cutting costs by shortening timeframes for developing therapies needed by patients worldwide."
The second major release this year of goBalto Activate, which enhances risk management in clinical trials, is critical in light of goBalto's continued growth. During the first half of 2015, goBalto saw a significant increase in customer usage and adoption.
Jadhav adding, "goBalto's momentum is industry validation of our ability to improve business performance and enhance visibility into the traditionally cumbersome process of activating sites for clinical trials. Our customers are able to reduce cycle times by > 30%, which translates into millions of dollars in savings."